0001104659-22-005596.txt : 20220119
0001104659-22-005596.hdr.sgml : 20220119
20220119203104
ACCESSION NUMBER: 0001104659-22-005596
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220114
FILED AS OF DATE: 20220119
DATE AS OF CHANGE: 20220119
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Bellemin Jean-Marc
CENTRAL INDEX KEY: 0001754253
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36860
FILM NUMBER: 22540348
MAIL ADDRESS:
STREET 1: C/O GRITSTONE ONCOLOGY, INC.
STREET 2: 5858 HORTON STREET, SUITE 210
CITY: EMERYVILLE
STATE: CA
ZIP: 94608
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IOVANCE BIOTHERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001425205
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 753254381
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 999 SKYWAY ROAD
STREET 2: SUITE 150
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 6502607120
MAIL ADDRESS:
STREET 1: 999 SKYWAY ROAD
STREET 2: SUITE 150
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: Lion Biotechnologies, Inc.
DATE OF NAME CHANGE: 20131015
FORMER COMPANY:
FORMER CONFORMED NAME: Genesis Biopharma, Inc
DATE OF NAME CHANGE: 20100319
FORMER COMPANY:
FORMER CONFORMED NAME: FREIGHT MANAGEMENT CORP
DATE OF NAME CHANGE: 20080128
4
1
tm223806-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-01-14
0
0001425205
IOVANCE BIOTHERAPEUTICS, INC.
IOVA
0001754253
Bellemin Jean-Marc
C/O IOVANCE BIOTHERAPEUTICS, INC.
825 INDUSTRIAL ROAD, 4TH FLOOR
SAN CARLOS
CA
94070
0
1
0
0
Chief Financial Officer
Stock Option (right to buy)
15.49
2022-01-14
4
A
0
135000
0
A
2032-01-14
Common Stock
135000
135000
D
Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.
/s/ Jean-Marc Bellemin
2022-01-19